X @The Wall Street Journal

Eli Lilly continued its recent buying spree, agreeing to pay up to $2.3 billion for Ajax Therapeutics in a deal that bolsters the drugmaker’s blood-cancer portfolio https://t.co/OKVACn0UJq ...